Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo

Carlo Giussani, Giorgio Carrabba, Mauro Pluderi, Valeria Lucini, Marilou Pannacci, Dario Caronzolo, Francesco Costa, Matteo Minotti, Giustino Tomei, Roberto Villani, Andreas Bikfalvi, Lorenzo Bello

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The systemic administration of endogenous inhibitors significantly reduced the growth of human glioma in vivo, but required the production of a large amount of biologically active protein. In this study we reduced the amount of protein needed and optimized the therapeutical response by delivering the endogenous inhibitors locally into the brain by osmotic minipumps. Human hemopexin fragment of MMP-2 or COOH-terminal fragment of platelet factor-4 were delivered locally and continuously into the brain of mice implanted intracranially with glioma cells, by osmotic minipumps connected to an intracranial catheter. Local delivery of human hemopexin fragment of MMP-2 and COOH-terminal fragment of platelet factor-4 significantly inhibited the growth of well-established malignant glioma in nude and BALB/C mice. When the inhibitors were given at the same concentration, the efficacy of the local delivery was much higher than that reached with the systemic administration, both when the inhibitor was administered daily or continuously by s.c. minipumps. Moreover, the local delivery reduced the amount of protein needed to reach a significant therapeutic response. Intracerebral delivery maintained a long-term control of glioma growth and inhibited glioma recurrence in a surgical resection model. Treatment showed no side effects. Histochemical analysis of tumors showed that the tumor growth inhibition was the result of a decrease in tumor vasculature and a change in tumor vessel morphology. Our data demonstrate that local intracerebral delivery of endogenous inhibitors effectively inhibits malignant glioma growth and reduces the amount of protein needed to reach a therapeutical response.

Original languageEnglish
Pages (from-to)2499-2505
Number of pages7
JournalCancer Research
Volume63
Issue number10
Publication statusPublished - May 15 2003

Fingerprint

Glioma
Growth
Hemopexin
Platelet Factor 4
Matrix Metalloproteinases
Neoplasms
Proteins
Inbred BALB C Mouse
Anatomic Models
Brain
Catheters
Recurrence

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. / Giussani, Carlo; Carrabba, Giorgio; Pluderi, Mauro; Lucini, Valeria; Pannacci, Marilou; Caronzolo, Dario; Costa, Francesco; Minotti, Matteo; Tomei, Giustino; Villani, Roberto; Bikfalvi, Andreas; Bello, Lorenzo.

In: Cancer Research, Vol. 63, No. 10, 15.05.2003, p. 2499-2505.

Research output: Contribution to journalArticle

Giussani, C, Carrabba, G, Pluderi, M, Lucini, V, Pannacci, M, Caronzolo, D, Costa, F, Minotti, M, Tomei, G, Villani, R, Bikfalvi, A & Bello, L 2003, 'Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo', Cancer Research, vol. 63, no. 10, pp. 2499-2505.
Giussani, Carlo ; Carrabba, Giorgio ; Pluderi, Mauro ; Lucini, Valeria ; Pannacci, Marilou ; Caronzolo, Dario ; Costa, Francesco ; Minotti, Matteo ; Tomei, Giustino ; Villani, Roberto ; Bikfalvi, Andreas ; Bello, Lorenzo. / Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo. In: Cancer Research. 2003 ; Vol. 63, No. 10. pp. 2499-2505.
@article{54111e1f75af41fb8bdb077a204a65d5,
title = "Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo",
abstract = "The systemic administration of endogenous inhibitors significantly reduced the growth of human glioma in vivo, but required the production of a large amount of biologically active protein. In this study we reduced the amount of protein needed and optimized the therapeutical response by delivering the endogenous inhibitors locally into the brain by osmotic minipumps. Human hemopexin fragment of MMP-2 or COOH-terminal fragment of platelet factor-4 were delivered locally and continuously into the brain of mice implanted intracranially with glioma cells, by osmotic minipumps connected to an intracranial catheter. Local delivery of human hemopexin fragment of MMP-2 and COOH-terminal fragment of platelet factor-4 significantly inhibited the growth of well-established malignant glioma in nude and BALB/C mice. When the inhibitors were given at the same concentration, the efficacy of the local delivery was much higher than that reached with the systemic administration, both when the inhibitor was administered daily or continuously by s.c. minipumps. Moreover, the local delivery reduced the amount of protein needed to reach a significant therapeutic response. Intracerebral delivery maintained a long-term control of glioma growth and inhibited glioma recurrence in a surgical resection model. Treatment showed no side effects. Histochemical analysis of tumors showed that the tumor growth inhibition was the result of a decrease in tumor vasculature and a change in tumor vessel morphology. Our data demonstrate that local intracerebral delivery of endogenous inhibitors effectively inhibits malignant glioma growth and reduces the amount of protein needed to reach a therapeutical response.",
author = "Carlo Giussani and Giorgio Carrabba and Mauro Pluderi and Valeria Lucini and Marilou Pannacci and Dario Caronzolo and Francesco Costa and Matteo Minotti and Giustino Tomei and Roberto Villani and Andreas Bikfalvi and Lorenzo Bello",
year = "2003",
month = "5",
day = "15",
language = "English",
volume = "63",
pages = "2499--2505",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "10",

}

TY - JOUR

T1 - Local intracerebral delivery of endogenous inhibitors by osmotic minipumps effectively suppresses glioma growth in vivo

AU - Giussani, Carlo

AU - Carrabba, Giorgio

AU - Pluderi, Mauro

AU - Lucini, Valeria

AU - Pannacci, Marilou

AU - Caronzolo, Dario

AU - Costa, Francesco

AU - Minotti, Matteo

AU - Tomei, Giustino

AU - Villani, Roberto

AU - Bikfalvi, Andreas

AU - Bello, Lorenzo

PY - 2003/5/15

Y1 - 2003/5/15

N2 - The systemic administration of endogenous inhibitors significantly reduced the growth of human glioma in vivo, but required the production of a large amount of biologically active protein. In this study we reduced the amount of protein needed and optimized the therapeutical response by delivering the endogenous inhibitors locally into the brain by osmotic minipumps. Human hemopexin fragment of MMP-2 or COOH-terminal fragment of platelet factor-4 were delivered locally and continuously into the brain of mice implanted intracranially with glioma cells, by osmotic minipumps connected to an intracranial catheter. Local delivery of human hemopexin fragment of MMP-2 and COOH-terminal fragment of platelet factor-4 significantly inhibited the growth of well-established malignant glioma in nude and BALB/C mice. When the inhibitors were given at the same concentration, the efficacy of the local delivery was much higher than that reached with the systemic administration, both when the inhibitor was administered daily or continuously by s.c. minipumps. Moreover, the local delivery reduced the amount of protein needed to reach a significant therapeutic response. Intracerebral delivery maintained a long-term control of glioma growth and inhibited glioma recurrence in a surgical resection model. Treatment showed no side effects. Histochemical analysis of tumors showed that the tumor growth inhibition was the result of a decrease in tumor vasculature and a change in tumor vessel morphology. Our data demonstrate that local intracerebral delivery of endogenous inhibitors effectively inhibits malignant glioma growth and reduces the amount of protein needed to reach a therapeutical response.

AB - The systemic administration of endogenous inhibitors significantly reduced the growth of human glioma in vivo, but required the production of a large amount of biologically active protein. In this study we reduced the amount of protein needed and optimized the therapeutical response by delivering the endogenous inhibitors locally into the brain by osmotic minipumps. Human hemopexin fragment of MMP-2 or COOH-terminal fragment of platelet factor-4 were delivered locally and continuously into the brain of mice implanted intracranially with glioma cells, by osmotic minipumps connected to an intracranial catheter. Local delivery of human hemopexin fragment of MMP-2 and COOH-terminal fragment of platelet factor-4 significantly inhibited the growth of well-established malignant glioma in nude and BALB/C mice. When the inhibitors were given at the same concentration, the efficacy of the local delivery was much higher than that reached with the systemic administration, both when the inhibitor was administered daily or continuously by s.c. minipumps. Moreover, the local delivery reduced the amount of protein needed to reach a significant therapeutic response. Intracerebral delivery maintained a long-term control of glioma growth and inhibited glioma recurrence in a surgical resection model. Treatment showed no side effects. Histochemical analysis of tumors showed that the tumor growth inhibition was the result of a decrease in tumor vasculature and a change in tumor vessel morphology. Our data demonstrate that local intracerebral delivery of endogenous inhibitors effectively inhibits malignant glioma growth and reduces the amount of protein needed to reach a therapeutical response.

UR - http://www.scopus.com/inward/record.url?scp=0038519967&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038519967&partnerID=8YFLogxK

M3 - Article

VL - 63

SP - 2499

EP - 2505

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 10

ER -